Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO’22
Provided By Globe Newswire
Last update: Feb 22, 2022
SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today shared two poster presentations that were presented during the 17th Congress of the European Crohn’s and Colitis Organisation (ECCO) on February 18, 2022.
